Contributions
Abstract: PB2470
Type: Publication Only
Background
In the era of newer immune-modulatory drugs, lot of debate is there on role and timing of Autologous bone marrow Transplantation. We conducted this study to look at the efficacy of RVD combination chemotherapy followed by an Autologous bone marrow transplant in 52 eligible Indian Myeloma patients.
Aims
We conducted this study to look at the efficacy of RVD combination chemotherapy followed by an Autologous bone marrow transplant in 52 eligible Indian Myeloma patients.
Methods
Eligible patients were treated according to this protocol. RVD q 21 days (3 cycles) Lenalidomide 10mg x 14 days every 21 day cycle, Bortezomib 2mg 1,4,8,11, Dexa 20mg 1,2,4,5,8,9,11,12. Then Collection of peripheral blood stem cells (PBSCs) using GCSF+/-Plerixafor. Autologous stem cell transplant: Melphalan 200mg/m2: Day -1, Re-infusion of PBSCs. Then maintenance Lenalidomide 10 mg 21 days every 28 days till progression.
Results
Results: 75% entered the transplant after three cycles of RVD after achieving a minimum of VGPR . The response rated to RVD were more than 95%. All entered the maintenance phase. The median followup was 24 months. In the transplantation group, 8 patients had disease progression, and symptomatic patients received a second-line therapy. Of the patients who were treated for disease progression, three underwent a second transplantation at the time of progression and one underwent Allogeneic transplantation.
Conclusion
Conclusions: In conclusion, we found that early consolidation therapy with high-dose chemotherapy plus transplantation was associated with longer progression-free survival. This benefit must be weighed against the increased risk of toxic effects associated with high-dose chemotherapy plus transplantation. This is a feasible option in Indian patients both in response rates as well as finances.
Session topic: 23. Stem cell transplantation - Clinical
Keyword(s): Myeloma
Abstract: PB2470
Type: Publication Only
Background
In the era of newer immune-modulatory drugs, lot of debate is there on role and timing of Autologous bone marrow Transplantation. We conducted this study to look at the efficacy of RVD combination chemotherapy followed by an Autologous bone marrow transplant in 52 eligible Indian Myeloma patients.
Aims
We conducted this study to look at the efficacy of RVD combination chemotherapy followed by an Autologous bone marrow transplant in 52 eligible Indian Myeloma patients.
Methods
Eligible patients were treated according to this protocol. RVD q 21 days (3 cycles) Lenalidomide 10mg x 14 days every 21 day cycle, Bortezomib 2mg 1,4,8,11, Dexa 20mg 1,2,4,5,8,9,11,12. Then Collection of peripheral blood stem cells (PBSCs) using GCSF+/-Plerixafor. Autologous stem cell transplant: Melphalan 200mg/m2: Day -1, Re-infusion of PBSCs. Then maintenance Lenalidomide 10 mg 21 days every 28 days till progression.
Results
Results: 75% entered the transplant after three cycles of RVD after achieving a minimum of VGPR . The response rated to RVD were more than 95%. All entered the maintenance phase. The median followup was 24 months. In the transplantation group, 8 patients had disease progression, and symptomatic patients received a second-line therapy. Of the patients who were treated for disease progression, three underwent a second transplantation at the time of progression and one underwent Allogeneic transplantation.
Conclusion
Conclusions: In conclusion, we found that early consolidation therapy with high-dose chemotherapy plus transplantation was associated with longer progression-free survival. This benefit must be weighed against the increased risk of toxic effects associated with high-dose chemotherapy plus transplantation. This is a feasible option in Indian patients both in response rates as well as finances.
Session topic: 23. Stem cell transplantation - Clinical
Keyword(s): Myeloma